WOOGENE B&G CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,115 KRW | +1.64% |
|
+2.11% | -8.98% |
| Sales 2022 | 43.7B 31.77M 2.65B | Sales 2023 | 57.92B 42.11M 3.51B | Capitalization | 35.39B 25.73M 2.15B |
|---|---|---|---|---|---|
| Net income 2022 | 850M 618K 51.56M | Net income 2023 | -1.18B -861K -71.82M | EV / Sales 2022 | 0.9 x |
| Net cash position 2022 | 5.37B 3.9M 326M | Net Debt 2023 | 10.95B 7.96M 664M | EV / Sales 2023 | 0.8 x |
| P/E ratio 2022 |
53.1
x | P/E ratio 2023 |
-29.9
x | Employees | 92 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 77.59% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.64% | ||
| 1 week | +2.11% | ||
| Current month | -1.68% | ||
| 1 month | -1.68% | ||
| 3 months | -6.22% | ||
| 6 months | -7.16% | ||
| Current year | -8.98% |
1 week
1 086.00
1 122.00
1 month
1 083.001 174.00
Current year
1 083.001 259.00
1 year
1 083.002 095.00
3 years
1 083.003 515.00
5 years
1 083.004 485.00
10 years
1 083.008 614.72
| Managers | Title | Age | Since |
|---|---|---|---|
Seok-Jin Kang
CEO | Chief Executive Officer | 81 | 17/85/17 |
Jae-Goo Kang
CEO | Chief Executive Officer | 54 | 01/01/01 |
Sang-Young Lee
AUD | Comptroller/Controller/Auditor | 82 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Seok-Jin Kang
CEO | Chief Executive Officer | 81 | 17/85/17 |
Jae-Goo Kang
CEO | Chief Executive Officer | 54 | 01/01/01 |
Hwa-Soon Kang
BRD | Director/Board Member | 63 | 30/22/30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 1,115 | +1.64% | 35,763 |
| 29/24/29 | 1,097 | +0.27% | 16,686 |
| 26/24/26 | 1,094 | -0.45% | 26,052 |
| 25/24/25 | 1,099 | +0.64% | 32,755 |
| 24/24/24 | 1,092 | +0.18% | 12,273 |
End-of-day quote Korea S.E., April 30, 2024
More quotes
WooGene B&G Co., Ltd. is a Korea-based company mainly engaged in the manufacture of veterinary drugs. The Companyâs products include anti-infective, bulk materials, probiotics, enzymes, antiparasitics, hormone preparations, vaccines, aquacultures, anesthetics, teat dips, disinfectants, pet cure drugs, calcium injections, antiphlogistic injections, enhance metabolism injections, diarrhea remedy injections, sedative injections for swine, toxin binders, pigmentation drugs and others. The Company also provides anti-inflammatory enzymes under the brand name SKD, which are used for human beings. The Company distributes its products within domestic market and to overseas markets, including Iran, Vietnam, Philippines, Brazil and others.
Sector
Pharmaceuticals
Calendar
09/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -8.98% | 23.28M | |
| -11.74% | 6.48B | |
| +24.75% | 3.7B | |
| -3.34% | 3.1B | |
| -1.52% | 1.44B | |
| -15.13% | 1.37B | |
| -25.63% | 1.24B | |
| -8.11% | 1.19B | |
| -10.84% | 1.17B | |
| -.--% | 1.05B |
- Stock Market
- Equities
- A018620 Stock
